Antiplatelet therapy after noncardioembolic stroke
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Antiplatelet therapy after noncardioembolic stroke
Author(s) :
Greving, Jacoba P. [Auteur]
Diener, Hans-Christoph [Auteur]
Reitsma, Johannes B. [Auteur]
Bath, Philip M. W. [Auteur]
Csiba, Laszlo [Auteur]
Hacke, Werner [Auteur]
Kappelle, L. Jaap [Auteur]
Koudstaal, Peter J. [Auteur]
LEYS, Didier [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Mas, Jean-Louis [Auteur]
Sacco, Ralph L. [Auteur]
Algra, Ale [Auteur]
Diener, Hans-Christoph [Auteur]
Reitsma, Johannes B. [Auteur]
Bath, Philip M. W. [Auteur]
Csiba, Laszlo [Auteur]
Hacke, Werner [Auteur]
Kappelle, L. Jaap [Auteur]
Koudstaal, Peter J. [Auteur]
LEYS, Didier [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Mas, Jean-Louis [Auteur]
Sacco, Ralph L. [Auteur]
Algra, Ale [Auteur]
Journal title :
Stroke
Abbreviated title :
Stroke
Pages :
STROKEAHA118024497
Publication date :
2019-06-10
ISSN :
1524-4628
English keyword(s) :
efficacy
antiplatelet agents
myocardial infarction
secondary prevention
stroke
antiplatelet agents
myocardial infarction
secondary prevention
stroke
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical ...
Show more >Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adjNMA-adjNMA-adjNMA-adjNMA-adjShow less >
Show more >Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adjNMA-adjNMA-adjNMA-adjNMA-adjShow less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2019-11-27T13:37:47Z